Black Diamond Therapeutics, Inc. (BDTX)
| Market Cap | 155.25M |
| Revenue (ttm) | 70.00M |
| Net Income (ttm) | 22.37M |
| Shares Out | 57.29M |
| EPS (ttm) | 0.39 |
| PE Ratio | 6.95 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 691,625 |
| Open | 2.890 |
| Previous Close | 2.920 |
| Day's Range | 2.690 - 2.940 |
| 52-Week Range | 1.460 - 4.940 |
| Beta | 3.39 |
| Analysts | Strong Buy |
| Price Target | 9.50 (+250.55%) |
| Earnings Date | May 8, 2026 |
About BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BDTX stock is "Strong Buy." The 12-month stock price target is $9.5, which is an increase of 250.55% from the latest price.
News
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Silevertinib, a fourth-generation EGFR inhibitor, shows strong efficacy and CNS activity in non-classical EGFR NSCLC and is advancing into a pivotal GBM trial. Key PFS data in NSCLC are expected in Q2 2024, with GBM trial enrollment starting soon and results anticipated in 2028.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Silevertinib’s Phase II data in non-classical EGFR-mutant lung cancer showed a 60% response rate and strong CNS activity, with durability and PFS data expected in Q2 2026. Plans include FDA engagement, a pivotal trial, and a Phase II GBM study, supported by a strong financial runway.
Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classic...
Black Diamond Therapeutics Transcript: Study Update
Silevertinib demonstrated a 60% response rate and robust CNS activity in frontline NSCLC patients with non-classical EGFR mutations, with efficacy maintained after dose reductions. A randomized phase II trial in newly diagnosed GBM patients with EGFR variant 3 will launch, focusing on high unmet need and leveraging silevertinib's strong brain penetrance.
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing...
Black Diamond Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Silevertinib is advancing as a brain-penetrant EGFR inhibitor for non-small cell lung cancer and glioblastoma, targeting a broad range of mutations with promising early efficacy and tolerability. Key data updates and partnership decisions are expected in the coming quarters.
Black Diamond Therapeutics Transcript: Stifel 2025 Healthcare Conference
Silevertinib, a brain-penetrant EGFR inhibitor, is advancing in phase 2 for non-classical EGFR-mutant lung cancer and glioblastoma, with key data expected this quarter. The drug targets a broad mutation spectrum, with a $2B+ market opportunity and pivotal phase 3 planned next year.
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive we...
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2025
A fourth-generation EGFR TKI is advancing in phase II for frontline non-small cell lung cancer, targeting non-classical mutations with strong CNS activity and a favorable safety profile. A pivotal phase III trial is planned, with accelerated approval possible by 2029. Key data readouts and regulatory updates are expected later this year.
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m...
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m...
Black Diamond Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum
The company is advancing its lead oral therapy, 1535, for non-classical EGFR mutant NSCLC, with a focus on frontline patients and broad mutation coverage. A recent partnership has extended cash runway, enabling pivotal development and a Q4 2024 data and FDA update.
Black Diamond Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference
BDTX-1535, an oral fourth-generation EGFR inhibitor, is advancing in NSCLC and GBM with broad activity across mutation types and a favorable safety profile. Key phase II data in frontline NSCLC and regulatory updates are expected in Q4 2024, with additional GBM data in 2025.
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. ...
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference
A fourth-generation EGFR inhibitor is advancing through phase 2 trials, showing robust efficacy and favorable tolerability in both recurrent and frontline non-small cell lung cancer, especially for non-classical and resistant mutations. Regulatory updates and mature data are expected in 1Q25.
Black Diamond Therapeutics Transcript: Stifel 2024 Healthcare Conference
BDTX-1535 demonstrated promising activity and tolerability in phase 2 for non-small cell lung cancer, with a 30%-40% response rate and a manageable safety profile. Strategic focus and financial runway support pivotal development, with key data updates expected in 2025.
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into...